PMID- 24405720
OWN - NLM
STAT- MEDLINE
DCOM- 20140915
LR  - 20220330
IS  - 1476-0711 (Electronic)
IS  - 1476-0711 (Linking)
VI  - 13
DP  - 2014 Jan 9
TI  - Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in 
      intensive care unit patients.
PG  - 7
LID - 10.1186/1476-0711-13-7 [doi]
AB  - BACKGROUND: The consumption of carbapenems has increased worldwide, together with 
      the increase in resistant gram negative bacilli. Subsequently, the prevalence of 
      carbapenem-resistant Acinetobacter infections has increased rapidly and become a 
      significant problem particularly in intensive care unit patients. The aim of the 
      present study was to evaluate the changes in the prevalence of Acinetobacter 
      infection by restricting the consumption of carbapenems in intensive care unit 
      patients. METHODS: This study was conducted between May 1, 2011 and February 28, 
      2013. The amount of carbapenem consumption and the number of patients with 
      multi-drug resistant Acinetobacter baumannii (MDRAB) isolates during the study 
      period were retrospectively obtained from the records of the patients, who were 
      hospitalized in the intensive care unit. The study period was divided into two 
      periods named as: Carbapenem non-restricted period (CNRP) and 
      carbapenem-restricted period (CRP). During CNRP, no restrictions were made on the 
      use of carbapenems. During CRP, the use of carbapenems was not allowed if there 
      was an alternative to carbapenems. Primary Endpoint: MDRAB infection after ICU 
      admission. The definition of nosocomial infections related to Acinetobacter spp. 
      was based on the criteria of the Center for Disease Control (CDC). The 
      correlation between the amount of carbapenem consumption and the number of 
      infections with MDRAB strains between the two periods were evaluated. RESULTS: 
      During the study period, a total of 1822 patients' (1053 patients in CNRP and 769 
      patients in CRP) records were evaluated retrospectively. A total of 10.82 defined 
      daily dose (DDD/100 ICU days) of anti-pseudomonal carbapenem were used in CNRP, 
      and this figure decreased to 6.95 DDD/100 ICU days in CRP. In the 8-month CNRP, 
      42 (3.98%) MDRAB-related nosocomial infections were detected, and 14 (1.82%) 
      infections were detected in CRP (p = 0.012). CONCLUSION: The prevalence of MDRAB 
      strains isolated in the CNRP was 2.24-fold higher than the prevalence in the CRP. 
      The prevalence of Acinetobacter infections can be reduced by taking strict 
      isolation measures as well as by implementing good antibiotics usage policy.
FAU - Ogutlu, Aziz
AU  - Ogutlu A
AD  - Sakarya University, Faculty of Medicine, Department of Infectious Diseases and 
      Clinical Microbiology, Sakarya, Turkey. drogutlu@hotmail.com.
FAU - Guclu, Ertugrul
AU  - Guclu E
FAU - Karabay, Oguz
AU  - Karabay O
FAU - Utku, Aylin Calica
AU  - Utku AC
FAU - Tuna, Nazan
AU  - Tuna N
FAU - Yahyaoglu, Mehmet
AU  - Yahyaoglu M
LA  - eng
PT  - Journal Article
DEP - 20140109
PL  - England
TA  - Ann Clin Microbiol Antimicrob
JT  - Annals of clinical microbiology and antimicrobials
JID - 101152152
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Carbapenems)
SB  - IM
MH  - Acinetobacter Infections/*epidemiology/microbiology
MH  - Acinetobacter baumannii/drug effects/*isolation & purification
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Carbapenems/*therapeutic use
MH  - Cross Infection/*epidemiology/microbiology
MH  - Drug Prescriptions/standards
MH  - Drug Resistance, Multiple, Bacterial
MH  - *Drug Utilization/standards/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Infection Control/methods
MH  - Intensive Care Units
MH  - Male
MH  - Middle Aged
MH  - Organizational Policy
MH  - Prevalence
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC3898784
EDAT- 2014/01/11 06:00
MHDA- 2014/09/16 06:00
PMCR- 2014/01/09
CRDT- 2014/01/11 06:00
PHST- 2013/11/15 00:00 [received]
PHST- 2014/01/01 00:00 [accepted]
PHST- 2014/01/11 06:00 [entrez]
PHST- 2014/01/11 06:00 [pubmed]
PHST- 2014/09/16 06:00 [medline]
PHST- 2014/01/09 00:00 [pmc-release]
AID - 1476-0711-13-7 [pii]
AID - 10.1186/1476-0711-13-7 [doi]
PST - epublish
SO  - Ann Clin Microbiol Antimicrob. 2014 Jan 9;13:7. doi: 10.1186/1476-0711-13-7.